The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis

NCT03314831 | Completed

• 1 other identifier: ACMYR-001
• Study Type: observational
• Target: 282
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to measure serum levels of myristic acid in septic patients and to compare them with myristic acid serum levels in patients with Systemic Inflammatory Response Syndrome of non infective etiology and in healthy volunteers. Furthermore, other biomarkers of sepsis are evaluated in comparison with microbiological findings detected either by standard hemocultures or by molecular biological methods.

Conditions

Sepsis Syndrome; Systemic Inflammatory Response Syndrome

Keywords

sepsis; septic shock; systemic inflammatory response syndrome; tetradecanoic acid; myristic acid

Outcome Measures

Primary Outcomes (1)

• Serum concentration of Myristic Acid

  Serum concentration of Myristic Acid in patients with sepsis or septic shock. Comparison with serum levels of Myristic Acid in patients with systemic inflammatory response syndrome non-infectious etiology and with subjects without systemic inflammation.

  5 days

Secondary Outcomes (1)

• Correlation of serum concentration of procalcitonin with detection of microbial agents in blood

  5 days

Study Arms (3)

Sepsis

Patients with sepsis or septic shock admitted on Intensive Care Unit.

Systemic Inflammatory Response Syndrome

Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.

No inflammation

Patients without systemic inflammation.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients admitted to ICU in study group, patients with Systemic Inflammatory Response Syndrome after surgery in SIRS group and subjects without systemic inflammation in control group.

You may qualify if:

• Sepsis or septic shock.
• Systemic inflammatory response syndrome.
• Subjects without systemic inflammation.

Sponsors & Collaborators

• Charles University, Czech Republic: lead

Study Sites (1)

Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer Hospital

Prague, 14059, Czechia

Location

Related Publications (5)

• Kauppi AM, Edin A, Ziegler I, Molling P, Sjostedt A, Gylfe A, Stralin K, Johansson A. Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room. PLoS One. 2016 Jan 22;11(1):e0147670. doi: 10.1371/journal.pone.0147670. eCollection 2016.

  PMID: 26800189 BACKGROUND

• Cambiaghi A, Pinto BB, Brunelli L, Falcetta F, Aletti F, Bendjelid K, Pastorelli R, Ferrario M. Characterization of a metabolomic profile associated with responsiveness to therapy in the acute phase of septic shock. Sci Rep. 2017 Aug 29;7(1):9748. doi: 10.1038/s41598-017-09619-x.

  PMID: 28851978 BACKGROUND

• Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta. 2015 Feb 2;440:97-103. doi: 10.1016/j.cca.2014.11.012. Epub 2014 Nov 18.

  PMID: 25447700 BACKGROUND

• Prucha M, Zazula R, Russwurm S. Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment? Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):37-49. doi: 10.1007/s00005-016-0415-9. Epub 2016 Aug 24.

  PMID: 27554587 BACKGROUND

• Zazula R, Prucha M, Tyll T, Kieslichova E. Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin. Crit Care. 2007;11(6):R131. doi: 10.1186/cc6202.

  PMID: 18088403 BACKGROUND

MeSH Terms

Conditions

Systemic Inflammatory Response Syndrome; Sepsis; Shock, Septic

Condition Hierarchy (Ancestors)

Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Shock; Infections

Study Officials

• Roman Zazula, MD

  Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of the Department of Anesthesiology and Critical Care

Study Record Dates

• First Submitted: October 16, 2017
• First Posted: October 19, 2017
• Study Start: October 24, 2017
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2022
• Last Updated: February 14, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

CZ (1)